Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
This is an autologous cell-based cancer vaccine composed of CD34+ hematopoietic progenitor cell-derived Langerhans-type dendritic cells (LCs) that have been electroporated with messenger RNA (mRNA) encoding three tumor-associated antigens: CT7, MAGE-A3, and Wilms tumor 1 (WT1). The process involves collecting stem cells from the patient for transplantation and using a portion to generate dendritic cells in vitro. These dendritic cells are then loaded with the specified antigen-encoding mRNAs via electroporation. When administered subcutaneously as a vaccine after autologous stem cell transplantation (ASCT), these modified LCs present the encoded antigens to T-cells, aiming to stimulate robust antigen-specific CD4+ and CD8+ T-cell responses against multiple myeloma tumor cells expressing these antigens. The approach is designed to enhance immune surveillance and reduce relapse risk post-transplantation by broadening the anti-tumor immune response[2][3][5].
- Other names
- autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cell vaccinetriple antigen-bearing mRNA-electroporated autologous LC vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells.